Show simple item record

dc.contributor.authorLunt, S
dc.contributor.authorCawthorne, Christopher
dc.contributor.authorAli, M
dc.contributor.authorTelfer, B
dc.contributor.authorBabur, M
dc.contributor.authorSmigova, A
dc.contributor.authorJulyan, Peter J
dc.contributor.authorPrice, Patricia M
dc.contributor.authorStratford, I
dc.contributor.authorBloomer, W
dc.contributor.authorPapadopoulou, M
dc.contributor.authorWilliams, K
dc.date.accessioned2010-09-14T09:51:55Z
dc.date.available2010-09-14T09:51:55Z
dc.date.issued2010-07-13
dc.identifier.citationThe hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. 2010, 103 (2):201-8 Br J Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid20588272
dc.identifier.doi10.1038/sj.bjc.6605753
dc.identifier.urihttp://hdl.handle.net/10541/111140
dc.description.abstractBACKGROUND: Metastases cause most cancer-related deaths. We investigated the use of hypoxia-selective cytotoxins as adjuvants to radiotherapy in the control of metastatic tumour growth. METHODS: The NLCQ-1, RB6145 and tirapazamine were assessed against the spontaneously metastasising KHT model. Subcutaneous KHT tumours (250 mm(3)) were irradiated with 25 Gy (single fraction) to control primary growth. Equitoxic drug treatments (NLCQ-1 (10 mg kg(-1)) once daily; RB6145 (75 mg kg(-1)) and tirapazamine (13 mg kg(-1)) twice daily) were administered 3-6 days post-radiotherapy when hypoxic cells were evident in lung micrometastases. Mice were culled when 50% of controls exhibited detrimental signs of lung metastases. RESULTS: In total, 95% of control mice presented with lung disease. This was significantly reduced by NLCQ-1 (33%; P=0.0002) and RB6145 (60%; P=0.02). Semi-quantitative grading of lung disease revealed a significant improvement with all treatments, with NLCQ-1 proving most efficacious (median grades: control, 4; NLCQ, 0 (P<0.0001); RB6145, 1 (P<0.001), tirapazamine, 3 (P=0.007)). Positron emission tomography (PET) was evaluated as a non-invasive means of assessing metastatic development. Primary and metastatic KHT tumours showed robust uptake of [(18)F]fluorodeoxyglucose ([(18)F]FDG). Metastatic burden discernable by [(18)F]FDG PET correlated well with macroscopic and histological lung analysis. CONCLUSION: The hypoxia-selective cytotoxin NLCQ-1 controls metastatic disease and may be a successful adjuvant to radiotherapy in the clinical setting.
dc.language.isoenen
dc.subjectTumour Cell Lineen
dc.subjectLung Canceren
dc.subjectCancer Metastasisen
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCell Hypoxia
dc.subject.meshCell Line, Tumor
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshCombined Modality Therapy
dc.subject.meshDrug Administration Schedule
dc.subject.meshDrug Evaluation, Preclinical
dc.subject.meshImidazoles
dc.subject.meshLung Neoplasms
dc.subject.meshMice
dc.subject.meshMice, Inbred C3H
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNitroimidazoles
dc.subject.meshQuinolines
dc.subject.meshSarcoma
dc.subject.meshTriazines
dc.titleThe hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.en
dc.typeArticleen
dc.contributor.departmentSchool of Pharmacy and Pharmaceutical Sciences, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractBACKGROUND: Metastases cause most cancer-related deaths. We investigated the use of hypoxia-selective cytotoxins as adjuvants to radiotherapy in the control of metastatic tumour growth. METHODS: The NLCQ-1, RB6145 and tirapazamine were assessed against the spontaneously metastasising KHT model. Subcutaneous KHT tumours (250 mm(3)) were irradiated with 25 Gy (single fraction) to control primary growth. Equitoxic drug treatments (NLCQ-1 (10 mg kg(-1)) once daily; RB6145 (75 mg kg(-1)) and tirapazamine (13 mg kg(-1)) twice daily) were administered 3-6 days post-radiotherapy when hypoxic cells were evident in lung micrometastases. Mice were culled when 50% of controls exhibited detrimental signs of lung metastases. RESULTS: In total, 95% of control mice presented with lung disease. This was significantly reduced by NLCQ-1 (33%; P=0.0002) and RB6145 (60%; P=0.02). Semi-quantitative grading of lung disease revealed a significant improvement with all treatments, with NLCQ-1 proving most efficacious (median grades: control, 4; NLCQ, 0 (P<0.0001); RB6145, 1 (P<0.001), tirapazamine, 3 (P=0.007)). Positron emission tomography (PET) was evaluated as a non-invasive means of assessing metastatic development. Primary and metastatic KHT tumours showed robust uptake of [(18)F]fluorodeoxyglucose ([(18)F]FDG). Metastatic burden discernable by [(18)F]FDG PET correlated well with macroscopic and histological lung analysis. CONCLUSION: The hypoxia-selective cytotoxin NLCQ-1 controls metastatic disease and may be a successful adjuvant to radiotherapy in the clinical setting.


This item appears in the following Collection(s)

Show simple item record